NCT03330782View on ClinicalTrials.gov

Remifentanil for Preventing Propofol Injection Pain in Elderly Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 16, 2017

Primary Completion Date

June 15, 2018

Study Completion Date

June 15, 2018

Conditions
Drug Usage
Interventions
DRUG

Remifentanil

Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in elderly patients (65-80 years)

DRUG

Remifentanil

Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in adult patients (20-60 years)

Trial Locations (1)

443-721

Jong Yeop Kim, Suwon

All Listed Sponsors
lead

Ajou University School of Medicine

OTHER

NCT03330782 - Remifentanil for Preventing Propofol Injection Pain in Elderly Patients | Biotech Hunter | Biotech Hunter